These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34757531)

  • 1. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis.
    Yanagisawa T; Mori K; Katayama S; Mostafaei H; Quhal F; Laukhtina E; Rajwa P; Motlagh RS; Aydh A; König F; Grossmann NC; Pradere B; Miki J; Kimura T; Egawa S; Shariat SF
    Int J Clin Oncol; 2022 Jan; 27(1):59-71. PubMed ID: 34757531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis.
    Mori K; Miura N; Mostafaei H; Quhal F; Motlagh RS; Lysenko I; Kimura S; Egawa S; Karakiewicz PI; Shariat SF
    Int J Clin Oncol; 2020 Aug; 25(8):1459-1474. PubMed ID: 32451768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.
    Yanagisawa T; Kawada T; Rajwa P; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; König F; Pallauf M; Pradere B; Karakiewicz PI; Nyirady P; Kimura T; Egawa S; Shariat SF
    Urol Oncol; 2023 Apr; 41(4):177-191. PubMed ID: 35970698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis.
    Kawada T; Yanagisawa T; Mostafaei H; Sari Motlagh R; Quhal F; Rajwa P; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pallauf M; Pradere B; Teoh JY; Karakiewicz PI; Araki M; Shariat SF
    Eur Urol Focus; 2023 Mar; 9(2):264-274. PubMed ID: 36774273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.
    Ogihara K; Kikuchi E; Shigeta K; Okabe T; Hattori S; Yamashita R; Yoshimine S; Shirotake S; Nakazawa R; Matsumoto K; Mizuno R; Hara S; Oyama M; Masuda T; Niwakawa M; Oya M
    Urol Oncol; 2020 Jun; 38(6):602.e1-602.e10. PubMed ID: 32139290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive Protein Is a Prognostic Factor for Survival in Metastatic Upper Tract Urothelial Carcinoma Patients Receiving Pembrolizumab.
    Nagasaka H; Yamamoto S; Suzuki A; Usui K; Terao H; Nakaigawa N; Kishida T
    In Vivo; 2024; 38(4):1823-1828. PubMed ID: 38936923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis.
    Mori K; Janisch F; Mostafaei H; Lysenko I; Kimura S; Egawa S; Shariat SF
    Urol Oncol; 2020 May; 38(5):315-333. PubMed ID: 32088103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study.
    Tanabe K; Kobayashi S; Maezawa Y; Ishihara K; Inoue N; Izumi K; Fujiwara M; Toide M; Yamamoto T; Uehara S; Araki S; Inoue M; Takazawa R; Numao N; Ohtsuka Y; Tanaka H; Yoshida S; Fujii Y
    Int J Clin Oncol; 2024 Sep; 29(9):1302-1310. PubMed ID: 38833113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.
    Mori K; Abufaraj M; Mostafaei H; Quhal F; Karakiewicz PI; Briganti A; Kimura S; Egawa S; Shariat SF
    J Urol; 2020 Dec; 204(6):1129-1140. PubMed ID: 32716694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma.
    Yamamoto Y; Yatsuda J; Shimokawa M; Fuji N; Aoki A; Sakano S; Yamamoto M; Suga A; Tei Y; Yoshihiro S; Kitahara S; Nagao K; Takai K; Kamiryo Y; Akao J; Yamaguchi S; Oba K; Shimabukuro T; Matsumoto H; Kamba T; Matsuyama H
    Int J Clin Oncol; 2021 Jan; 26(1):169-177. PubMed ID: 32948925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.
    Uchimoto T; Nakamura K; Komura K; Fukuokaya W; Yano Y; Nishimura K; Kinoshita S; Nishio K; Fukushima T; Nakamori K; Matsunaga T; Tsutsumi T; Tsujino T; Taniguchi K; Tanaka T; Uehara H; Takahara K; Inamoto T; Kimura T; Egawa S; Azuma H
    Urol Oncol; 2022 Jul; 40(7):344.e11-344.e17. PubMed ID: 35346572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
    BJU Int; 2021 Jan; 127(1):90-95. PubMed ID: 32662189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan.
    Fujiwara M; Yuasa T; Urasaki T; Komai Y; Fujiwara R; Numao N; Yamamoto S; Yonese J
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1398. PubMed ID: 33934570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Mori K; Mostafaei H; Enikeev DV; Lysenko I; Quhal F; Kimura S; Karakiewicz PI; Egawa S; Shariat SF
    J Urol; 2020 Jul; 204(1):58-62. PubMed ID: 31995432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-Analysis.
    Mori K; Janisch F; Parizi MK; Mostafaei H; Lysenko I; Kimura S; Enikeev DV; Egawa S; Shariat SF
    J Urol; 2020 Jun; 203(6):1075-1084. PubMed ID: 31479406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies.
    Wu S; Zhao X; Wang Y; Zhong Z; Zhang L; Cao J; Ai K; Xu R
    Cell Physiol Biochem; 2018; 46(4):1352-1364. PubMed ID: 29689562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort.
    Ito K; Kobayashi T; Kojima T; Hikami K; Yamada T; Ogawa K; Nakamura K; Sassa N; Yokomizo A; Abe T; Tsuchihashi K; Tatarano S; Inokuchi J; Tomida R; Fujiwara M; Takahashi A; Matsumoto K; Shimizu K; Araki H; Kurahashi R; Osaki Y; Tashiro Y; Uegaki M; Ogawa O; Kitamura H; Nishiyama H
    Cancer Med; 2021 May; 10(10):3188-3196. PubMed ID: 33931987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab.
    Kawashima A; Yamamoto Y; Sato M; Nakata W; Kakuta Y; Ishizuya Y; Yamaguchi Y; Yamamoto A; Yoshida T; Takayama H; Takada T; Inoue H; Okuda Y; Kato T; Hatano K; Uemura M; Nonomura N; Imamura R
    Sci Rep; 2021 Oct; 11(1):21199. PubMed ID: 34707147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic Organotropism Differential Treatment Response in Urothelial Carcinoma: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
    Kardoust Parizi M; Matsukawa A; Bekku K; Klemm J; Alimohammadi A; Laukhtina E; Karakiewicz P; Chiujdea S; Abufaraj M; Krauter J; Shariat SF
    Eur Urol Oncol; 2024 Aug; 7(4):663-676. PubMed ID: 37980251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
    Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
    Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.